Advertisement

Journal of Neuro-Oncology

, Volume 100, Issue 1, pp 65–71 | Cite as

A lower-dose, lower-toxicity cisplatin–etoposide regimen for childhood progressive low-grade glioma

  • Maura Massimino
  • Filippo Spreafico
  • Daria Riva
  • Veronica Biassoni
  • Geraldina Poggi
  • Carlo Solero
  • Lorenza Gandola
  • Lorenzo Genitori
  • Piergiorgio Modena
  • Fabio Simonetti
  • Paolo Potepan
  • Michela Casanova
  • Cristina Meazza
  • Carlo A. Clerici
  • Serena Catania
  • Iacopo Sardi
  • Felice Giangaspero
Clinical Study - Patient Study

Abstract

After successfully using cisplatin (30 mg/m2/day) and etoposide (150 mg/m2/day) in ten three-day courses for progressive low-grade gliomas, a subsequent protocol reduced the daily doses of cisplatin (to 25 mg) and etoposide (to 100 mg), with the objective of achieving the same response and three-year PFS rates with lower neurotoxicity and myelotoxicity. We treated 37 patients (median age 6 years); 23 had optochiasmatic tumours and nine were metastatic cases. Diagnoses were clinical in 13 cases and histological in 24, and comprised: pilocytic astrocytoma (17), ganglioglioma (3), pilomyxoid astrocytoma (2), and fibrillary astrocytoma (2). Treatment was prompted by radiological evidence of progression and/or clinical deterioration a median 18 months after the first diagnosis. After initial MRI staging, neurological and clinical examinations were performed before each chemotherapy cycle, with MRI after the first three courses and every three months thereafter. After a median 48 months, a volume reduction was appreciable in 24 cases (65%) and response was maximum 12 months after starting treatment. The three-year EFS and OS rates were 65 and 97%, respectively. Clinical, neurological, or functional improvements were seen in 26/37 cases. No children had a WBC nadir below 2,000/mm3. Audiological toxicity caused damage in 4/34 cases. The previous protocol had achieved volume reductions in 70% of cases, causing audiological damage (data updated) in 11/31 (P = 0.023), with three-year PFS and OS rates of 70 and 100%, respectively. Lower doses of cisplatin/etoposide are still effective in progressive low-grade glioma, with less acute and persistent morbidity.

Keywords

Childhood low-grade glioma Chemotherapy for brain tumours Ototoxicity Tumour response Symptom amelioration 

Notes

Acknowledgements

This paper was presented in part at the ISPNO, 13th International Symposium on Pediatric Neuro-Oncology: June 29–July 2, 2008 Chicago, USA. This paper was partly financed by the AIRC (Associazione Italiana per la Ricerca sul Cancro) and Associazione Bianca Garavaglia (Busto Arsizio, Varese).

References

  1. 1.
    Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN (1993) Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11:850–856PubMedGoogle Scholar
  2. 2.
    Gajjar A, Sanford RA, Heideman R, Jenkins JJ, Walter A, Li Y, Langston JW, Muhlbauer M, Boyett JM, Kun LE (1997) Low-grade astrocytoma: a decade of experience at St. Jude Children’s Research Hospital. J Clin Oncol 15:2792–2799PubMedGoogle Scholar
  3. 3.
    Petronio J, Edwards MS, Prados M, Freyberger S, Rabbitt J, Silver P, Levin VA (1991) Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg 74:701–708CrossRefPubMedGoogle Scholar
  4. 4.
    Laithier V, Grill J, Le Deley MC, Ruchoux MM, Couanet D, Doz F, Pichon F, Rubie H, Frappaz D, Vannier JP, Babin-Boilletot A, Sariban E, Chastagner P, Zerah M, Raquin MA, Hartmann O, Kalifa C (2003) Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy—results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 21:4572–4578CrossRefPubMedGoogle Scholar
  5. 5.
    Lafay-Cousin L, Holm S, Qaddoumi I, Nicolin G, Bartels U, Tabori U, Huang A, Bouffet E (2005) Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 103:2636–2642CrossRefPubMedGoogle Scholar
  6. 6.
    McLaughlin ME, Robson CD, Kieran MW, Jacks T, Pomeroy SL, Cameron S (2003) Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol 25:644–648CrossRefPubMedGoogle Scholar
  7. 7.
    Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, Riva D, Ruggiero A, Valentini L, Mazza E, Genitori L, Di Rocco C, Navarria P, Casanova M, Ferrari A, Luksch R, Terenziani M, Balestrini MR, Colosimo C, Fossati-Bellani F (2002) High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 20:4209–4216CrossRefPubMedGoogle Scholar
  8. 8.
    Gnekow AC (1995) Recommendations of the Brain Tumor Subcommittee for the reporting of trials: SIOP Brain Tumor Subcommittee—International Society of Pediatric Oncology. Med Pediatr Oncol 24:104–108CrossRefPubMedGoogle Scholar
  9. 9.
    Kaplan E, Meyer P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  10. 10.
    Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J (1991) Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19:295–300CrossRefPubMedGoogle Scholar
  11. 11.
    Gajjar A, Bhargava R, Jenkins JJ, Heideman R, Sanford RA, Langston JW, Walter AW, Kuttesch JF, Muhlbauer M, Kun LE (1995) Low-grade astrocytoma with neuraxis dissemination at diagnosis. J Neurosurg 83:67–71CrossRefPubMedGoogle Scholar
  12. 12.
    Fernandez C, Figarella-Branger D, Girard N, Bouvier-Labit C, Gouvernet J, Paz Paredes A, Lena G (2003) Pilocytic astrocytomas in children: prognostic factors—a retrospective study of 80 cases. Neurosurgery 53:544–555CrossRefPubMedGoogle Scholar
  13. 13.
    Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, Aldape KD, Albin MG, Emnett RJ, Loeser S, Watson MA, Nagarajan R, Gutmann DH (2007) Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res 67:890–900CrossRefPubMedGoogle Scholar
  14. 14.
    Fisher PG, Tihan T, Goldthwaite PT, Wharam MD, Carson BS, Weingart JD, Repka MX, Cohen KJ, Burger PC (2008) Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 51:245–250CrossRefPubMedGoogle Scholar
  15. 15.
    Korshunov A, Meyer J, Capper D (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118:401–405CrossRefPubMedGoogle Scholar
  16. 16.
    Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118:1739–1749CrossRefPubMedGoogle Scholar
  17. 17.
    De Carli E, Wang X, Puget S (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:2248 author reply 2249CrossRefPubMedGoogle Scholar
  18. 18.
    Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedGoogle Scholar
  19. 19.
    Tibbetts KM, Emnett RJ, Gao F, Perry A, Gutmann DH, Leonard JR (2009) Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathol 117:657–665CrossRefPubMedGoogle Scholar
  20. 20.
    Gutmann DH (2008) Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma. J Child Neurol 23:1186–1194CrossRefPubMedGoogle Scholar
  21. 21.
    Walker D (2003) Recent advances in optic nerve glioma with a focus on the young patient. Curr Opin Neurol 16:657–664CrossRefPubMedGoogle Scholar
  22. 22.
    Emanuel PD (2008) Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 22:1335–1342CrossRefPubMedGoogle Scholar
  23. 23.
    Smith MA, Rubinstein L, Anderson JR, Arthur D, Catalano PJ, Freidlin B, Heyn R, Khayat A, Krailo M, Land VJ, Miser J, Shuster J, Vena D (1999) Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 17:275–281Google Scholar
  24. 24.
    Shankar SM, Chen L, Zhou T, Krailo MD, Reaman G, Bhatia S (2008) Risk of therapy related myelodisplasia and acute myeloid leukemia (t-MDS/AML) in children exposed to alkylating agents, anthracyclines, platinum compounds and epipodophyllotoxins: a report from Children’s Oncology Grop (COG). J Clin Oncol 26 (abstr 10005)Google Scholar
  25. 25.
    Riva D, Massimino M, Giorgi C, Nichelli F, Erbetta A, Usilla A, Vago C, Bulgheroni S (2009) Cognition before and after chemotherapy alone in children with chiasmatic-hypothalamic tumors. J Neurooncol 92:49–56CrossRefPubMedGoogle Scholar
  26. 26.
    Puget S, Crimmins DW, Garnett MR, Grill J, Oliveira R, Boddaert N, Wray A, Lelouch-Tubiana A, Roujeau T, Di Rocco F, Zerah M, Sainte-Rose C (2007) Thalamic tumors in children: a reappraisal. J Neurosurg 106(5 Suppl):354–362PubMedGoogle Scholar
  27. 27.
    Jahraus CD, Tarbell NJ (2006) Optic pathway gliomas. Pediatr Blood Cancer 46:586–596CrossRefPubMedGoogle Scholar
  28. 28.
    Hug EB, Muenter MW, Archambeau JO, DeVries A, Liwnicz B, Loredo LN, Grove RI, Slater JD (2002) Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlenther Onkol 178:10–17CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Maura Massimino
    • 1
  • Filippo Spreafico
    • 1
  • Daria Riva
    • 5
  • Veronica Biassoni
    • 1
  • Geraldina Poggi
    • 7
  • Carlo Solero
    • 6
  • Lorenza Gandola
    • 2
  • Lorenzo Genitori
    • 8
  • Piergiorgio Modena
    • 4
  • Fabio Simonetti
    • 1
  • Paolo Potepan
    • 3
  • Michela Casanova
    • 1
  • Cristina Meazza
    • 1
  • Carlo A. Clerici
    • 1
  • Serena Catania
    • 1
  • Iacopo Sardi
    • 8
  • Felice Giangaspero
    • 9
  1. 1.Division of PaediatricsFond. IRCCS Istituto Nazionale TumoriMilanItaly
  2. 2.Division of RadiotherapyFond. IRCCS Istituto Nazionale TumoriMilanItaly
  3. 3.Division of RadiologyFond. IRCCS Istituto Nazionale TumoriMilanItaly
  4. 4.Molecular Biology UnitFond. IRCCS Istituto Nazionale TumoriMilanItaly
  5. 5.Department of Developmental NeurologyFond. IRCCS Istituto Neurologico C. BestaMilanItaly
  6. 6.Neurosurgery UnitFond. IRCCS Istituto Neurologico C. BestaMilanItaly
  7. 7.Acquired Lesions Division UnitIstituto Eugenio MedeaBosisio PariniItaly
  8. 8.Neurosurgery UnitOsp. MeyerFlorenceItaly
  9. 9.Neuropathology (FG) UnitUniversity La Sapienza 00151 Roma and NeuromedPozzilliItaly

Personalised recommendations